Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Has results × soluble LAG-3 protein, human × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 126 pembrolizumab 103 Nivolumab 91 Carboplatin 87 Paclitaxel 81 Rituximab 78 Dexamethasone 78 Gemcitabine 73 Lenalidomide 66 Radiotherapy 64 Cytarabine 64 Cisplatin 61 Bevacizumab 57 Etoposide 55 fludarabine phosphate 52 fludarabine 49 Docetaxel 48 Bortezomib 47 Temozolomide 44 Prednisone 42 Erlotinib Hydrochloride 42 Capecitabine 42 Everolimus 41 Ipilimumab 40 Doxorubicin 40 Melphalan 38 Fluorouracil 38 Filgrastim 38 Azacitidine 38 Vorinostat 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01308294 2020-06-11

LAG-3/IMP321

Centre Hospitalier Universitaire Vaudois

Phase 1/2 Terminated

16 enrolled 12 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡